louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06361615: Effect of a Dual-task Intervention Program on Physical and Cognitive Function
Official title: Effect of a Dual-task Intervention Program on Physical and Cognitive Function in Institutionalized Older Adults: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Functional Movement Disorder
Fragility
Keywords: dual task exercise
institutionalized
physical function
Lead sponsor: University of Americas
Sponsor class: OTHER
First posted: 2024-04-12
Enrollment: 24
Sex: ALL
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: TREATMENT

Brief summary: Aim: to compare the effects of single-task (ST) and dual-task (DT) training on physical and cognitive function in institutionalized older adults in 1 month.

Methods: Participants were assigned randomly into two groups, ST (multicomponent physical exercise) and DT training (multicomponent physical exercise + cognitive tasks). Both groups performed the exercise three times per week for 1 month. Short Physical Performance Battery (SPPB), handgrip strength, Barthel Index and Montreal Cognitive Assessment (MoCA) were used to assess physical and cognitive performance, respectively. Variables were measured at the beginning (V1),at the end of the exercise (V2), as well as one month later (V3). Paired Student's t-test and lineal logistic regressions models were used to explore the effect of the exercise interventions.


Eligibility criteria: Inclusion Criteria:

* Institutionalized older people between 65 and 75
* mild to moderate cognitive impairment

Exclusion Criteria:

* Acute or chronic pathologies that prevent exercise

Primary outcomes:
measure: Short Physical Performance Battery (SPPB)
timeFrame: 4 weeks
Secondary outcomes:
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: 4 weeks
measure: Barthel Index
timeFrame: 4 weeks
measure: Isometric Handgrip Strength (IHS)
timeFrame: 4 weeks
measure: Immobility Syndrome Scale
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Santiago de Chile
country: Chile
facility: Universidad de las Americas
state: Santiago
Study officials:
References:
Clinical trial NCT01679015: Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes
Official title: Concomitant Dry Eye in Patients With Ocular Allergy: an Under Recognized and Poorly Managed Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dry Eyes
Allergic Conjunctivitis
Keywords: Burning
Dryness
Itching
Blurry Vision
Lead sponsor: Schwartz Laser Eye Center
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2012-09-05
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients will be screened from existing patient database.

Brief summary: Evaluating the percentage of patients that suffer from eye allergies and determining whether they also have dry eyes.


Eligibility criteria: Inclusion Criteria:

* Ability to give informed consent
* Males and females at least 18 years of age
* Personal history of allergic disorders including but not limited to allergic conjunctivitis, allergic rhinitis, contact dermatitis and other eczema, and asthma
* Diagnosis of allergic conjunctivitis
* Presence of any of the following signs including conjunctival redness and papillae, chemosis, red edematous eyelids, reduced tear clearance, reduced TBUT, vital staining, stringy discharge, and/or symptoms including ocular itching, burning and tearing, runny nose or itchy throat

Exclusion Criteria:

* Active ocular or systemic infection
* History of ocular infection within past 6 months
* Presence of punctal plugs
* Recent ocular surgery within past 6 months
* Current use of chemotherapeutic agents
* Presence of ocular trauma
* Inability to give informed consent
* Women who are pregnant, nursing or lactating

Primary outcomes:
measure: Prevalence of dry eye in an allergic population presenting to a high volume optometry practice
timeFrame: up to 2 years
Secondary outcomes:
measure: Prevalence of allergic patients with moderate to severe ocular signs and symptoms
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Schwartz Laser Eye Center
state: Arizona
Study officials:
affiliation: Schwartz Laser Eye Center
name: Marc R Bloomenstein, O.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00423215: LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
Official title: An Open Therapeutic Observational Evaluation of the Efficacy and Safety Profile of Lantus in Everyday Medical Practice in Type 2 Diabetes Mellitus Patients, Who Start Receiving Lantus - Treated With Any Other Insulin, With A1c>7%
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-01-18
Enrollment: 1007
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Type II Diabetes

Brief summary: The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did not reach the target of A1c = 7%.


Eligibility criteria: Inclusion Criteria:

* Patients with type 2 diabetes mellitus,
* Having been treated with any other insulin, but who did not reach the target of A1c=7%.
* Ability and willingness to perform Self Monitoring Blood Glucose measurement

Exclusion Criteria:

* Will follow the prescribing information (Summary of Product Characteristics).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Measure of Glycolysated Haemoglobin (HbA1c) level reduction
timeFrame: Delta between the treatment start and the end of the study (i.e. 4 months +/- 2 weeks)
Secondary outcomes:
measure: Measure of Fasting Blood Glucose (FBG) level reduction
timeFrame: Delta between the treatment start and the end of the study (i.e. 4 months +/- 2 weeks)
measure: Investigator assessment
timeFrame: At the end of the study (i.e. 4 months +/- 2 weeks)
measure: Insulin dose
timeFrame: At the end of the study (i.e. 4 months +/- 2 weeks)
measure: Patient's satisfaction
timeFrame: At the end of the study (i.e. 4 months +/- 2 weeks)
Other outcomes:
Locations:
city: Natanya
country: Israel
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Nurit Tweezer-Zaks, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01534715: IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Official title: A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Lead sponsor: ImmunoGen, Inc.
Sponsor class: INDUSTRY
First posted: 2012-02-17
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).


Eligibility criteria: Inclusion Criteria:

* Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL).
* Adequate organ function
* ECOG ≤ 2
* Recovered or stabilized from prior treatments.

Exclusion Criteria:

* Allogeneic stem cell transplantation
* Pregnant or lactating females
* Known central nervous system, meningeal or epidural disease including brain metastases

Primary outcomes:
measure: Occurrence of dose limiting toxicities
timeFrame: During study
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: New York
country: United States
facility: Memorial Sloan-Kettering Cancer Center
state: New York
city: Columbus
country: United States
facility: Ohio State University
state: Ohio
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: San Antonio
country: United States
facility: CTRC at UTHSCSA
state: Texas
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
city: Bellinzona
country: Switzerland
facility: Oncology Institute of Southern Switzerland
Study officials:
References:
Clinical trial NCT06101615: Effects of IASTM vs. Foam Rolling on Knee and Hip Range of Motion in Soccer Players
Official title: Effects of Instrument Assisted Soft Tissue Mobilization vs. Foam Rolling on Knee and Hip Flexibility and Performance in Soccer Players
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Muscle Tightness
Keywords: FAT
Foam Rolling
IASTM
Joint Flexibility
Soccer
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-10-26
Enrollment: 10
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Concurrent Parallel Randomized Clinical Trial
Primary purpose: TREATMENT

Brief summary: The aim of this study is:

To compare the acute and long-term affects of instrument assisted soft tissue mobilization (IASTM) vs foam rolling on knee and hip flexibility and performance in soccer players.

Detailed description: The objective of this study is to compare the acute and long-term affects of instrument assisted soft tissue mobilization vs foam rolling on knee and hip flexibility and performance in soccer players. This is a randomized controlled trial, in which participants will be randomly divided into two groups: group-A and group-B. Group-A will receive intervention IASTM while Group-B will receive foam rolling as intervention. Intervention will be carried out for 8 weeks. Assessment of the range of motions for hip and knee joints will be carried out at baseline, immediately after the session, after four weeks and after five (5) months. The secondary measures of performance used in the study are sit and reach test, 100m sprint speed test, Illinois agility run test.

Eligibility criteria: Inclusion Criteria:

* Individuals with normal BMI
* Players with at least one year of playing professional soccer and taking at least three training sessions/matches per week.

Exclusion Criteria:

* Players with any pathological conditions affecting any of the system.
* Suffering from recent acute unhealed MSK injury/Trauma.

Primary outcomes:
measure: Knee Range of Motion (ROM)
timeFrame: Baseline, after 8 weeks, and after 5 months
Secondary outcomes:
measure: Knee Flexibility (Active Knee Extension Test)
timeFrame: Baseline, after 8 weeks, and after 5 months
measure: Knee Flexibility (Sit and Reach Test)
timeFrame: Baseline, after 8 weeks, and after 5 months
measure: Sprint Speed
timeFrame: Baseline, after 8 weeks, and after 5 months
measure: Agility
timeFrame: Baseline, after 8 weeks, and after 5 months
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Riphah International University (RIU)
state: Islamabad Capital Territory
Study officials:
affiliation: Riphah International University, Islamabad.
name: Noman Sadiq, MS-SPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04393415: Using PRP and Cord Blood in Treatment of Covid -19
Official title: the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Virus
Lead sponsor: Aljazeera Hospital
Sponsor class: OTHER
First posted: 2020-05-19
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: covid - 19 is a critical viral infection that affects humans

Detailed description: Covid -19 pandemic started was declared in 2020

Eligibility criteria: Inclusion Criteria:

* patients with positive covid -19 and has symptoms and isolated in the hospital

Exclusion Criteria:

* patients with negative test for covid -19

Primary outcomes:
measure: the number of patients with positive covid 19 who will improve after receiving stem cells
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Aljazeera( Al Gazeera) hospital
Study officials:
affiliation: Algezeera hospitaland National Research Centre ,Egypt
name: Mahmoud Alalfy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03583515: Evaluating Within-Person and Between-Person Effects Of A Personalized Normative Feedback Intervention On Drinking As They Are Moderated By Self-Determination
Official title: Self-Determination Theory as A Framework For Evaluating Within-Person Effects Of Personalized Normative Feedback On Drinking
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Drinking
Lead sponsor: University of Houston
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2018-07-11
Enrollment: 136
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Half of participants will be randomly assigned to receive personalized normative feedback about their drinking. The other half will be randomly assigned to receive control feedback about social media use.
Primary purpose: TREATMENT

Brief summary: This study evaluates within-person and between-person effects of a personalized normative feedback intervention and injunctive norms as they are altered by self-determination in heavy drinkers. Half of participants will receive personalized normative feedback and the other half will receive control feedback about media use habits.


Eligibility criteria: Inclusion Criteria:

* Student at the University of Houston
* Above 18 years of age
* Heavy drinker (more than 4 drinks \[women\] or 5 drinks \[men\] on a single occasion in the last 2.5 weeks and drinks, on average, at least once per week.

Primary outcomes:
measure: Between-Person Self-Determination by PNF Interaction Predicting Consumption
timeFrame: 2-4 Weeks
measure: Within-Person Self-Determination by PNF Interaction Predicting Consumption
timeFrame: 17 Days
Secondary outcomes:
measure: Between-Person Self-Determination by PNF Interaction Predicting Alcohol-Related Problems
timeFrame: 2-4 Weeks
measure: Within-Person Self-Determination by PNF Interaction Predicting Alcohol-Related Problems
timeFrame: 17 Days
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Houston
state: Texas
Study officials:
References:
Clinical trial NCT03358615: Robson Classification of Indications of Cesarean Section at MUH
Official title: Robson Classification of Indications of Cesarean Section at a University Hospital in Egypt
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Indication of Cesarean Section
Keywords: robson classification
Egypt
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2017-11-30
Enrollment: 700
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective study of an obstetric ,for booked (inpatient), non-booked (emergency) cases.

Full data sheet- from for the case (history, examination, diagnosis, pregnancy duration ,labor onset: spontaneous or induced , and previous pregnancy C.S or not

Brief summary: Robson classification of Cesarean section rates and indications allows evaluation and comparison of the contributors to the Cesarean section rate and their impact. It also allows comparison between institutions, regions, and countries that adopt this classification Robson's system classifies all deliveries into one of ten groups on the basis of five parameters: obstetric history (parity and previous cesarean section), onset of labor (spontaneous, induced, or cesarean section before onset of labor), fetal presentation or lie (cephalic, breech, or transverse), number of neonates, and gestational age (preterm or term; panel This study evaluates C.S rates and indications according to Robson classification in a University Hospital in a year (2016) to compare with international standards


Eligibility criteria: Inclusion Criteria:

* all cases who underwent CS at Mansoura University Hospital inpatients and emergency cases

Exclusion Criteria:

* non

Primary outcomes:
measure: Evaluation of C.S rates and indications according to Robson classification
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Mansourah
country: Egypt
facility: mansoura University
state: Dakahlia
Study officials:
References:
Clinical trial NCT05897515: LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia
Official title: LIAISON NES Flu A/B & COVID-19 Clinical Agreement in Australia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Influenza A
Influenza Type B
Coronavirus Disease 2019
Lead sponsor: DiaSorin Molecular LLC
Sponsor class: INDUSTRY
First posted: 2023-06-09
Enrollment: 233
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The DiaSorin Molecular LIAISON® NES FLU A/B \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors.

The LIAISON® NES FLU A/B \& COVID-19 assay is intended for use as an aid in the differential diagnosis of influenza A, influenza B and SARS-CoV-2 infection in a professional laboratory setting.

Negative results do not preclude influenza A, influenza B, or SARS-CoV-2, infection and should not be used as the sole basis for patient management decisions. The assay is not intended to detect the presence of the influenza C virus.


Eligibility criteria: Inclusion Criteria:

* Human patients with active signs and symptoms of respiratory tract infection at time of collection
* Specimens collected within 7 days of symptom onset for the initial collection
* Availability of age, gender, race, ethnicity, collection dates, collection time, routine respiratory testing method, routine respiratory result, signs and symptoms (e.g., fever), date of symptom onset for each symptom, vaccination status (Flu and COVID-19, as applicable), pre-existing medical conditions (as applicable), medications (e.g., COVID-19 antivirals), etc. for each subject

Exclusion Criteria:

* Incorrect swab type
* Incorrect transport media
* Incorrect specimen handling (specimens not stored at recommended temperature)
* Samples collected \>7 days from symptom onset
* Subjects not consented

Primary outcomes:
measure: Diagnostic accuracy
timeFrame: Samples will be tested on LIAISON NES within one hour of collection.
Secondary outcomes:
Other outcomes:
Locations:
city: Ballarat
country: Australia
facility: Grampians Health
state: Victoria
Study officials:
affiliation: DiaSorin Molecular/Luminex Corporation
name: Janet Farhang, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01591915: A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer
Official title: A Randomized Controlled Mindfulness Based Stress Reduction Intervention in Women With Breast Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Cancer
Keywords: Breast cancer, Mindfulness Based Stress Reduction, RCT, mood, cooping, health related quality of life
Lead sponsor: Skaraborg Hospital
Sponsor class: OTHER_GOV
First posted: 2012-05-04
Enrollment: 150
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to evaluate the effect of mindfulness based stress reduction intervention in women with breast cancer


Eligibility criteria: Inclusion Criteria:

* patients diagnosed with breast cancer after completion of adjuvant chemotherapy or radiation therapy, with/or without endocrine therapy

Exclusion Criteria:

* patients with advanced illness at diagnosis
* patients previously used MBSR

Primary outcomes:
measure: The efficacy of Mindfulness Based Stress Reduction on mood disorders
timeFrame: up to 5 years follow up
Secondary outcomes:
measure: Coping capacity and health-related quality of life
timeFrame: up to 5 years follow up
Other outcomes:
Locations:
city: Skövde
country: Sweden
facility: Skaraborg Hospital
state: Western Region
Study officials:
References:
citation: Kenne Sarenmalm E, Martensson LB, Holmberg SB, Andersson BA, Oden A, Bergh I. Mindfulness based stress reduction study design of a longitudinal randomized controlled complementary intervention in women with breast cancer. BMC Complement Altern Med. 2013 Oct 2;13:248. doi: 10.1186/1472-6882-13-248.
Clinical trial NCT02384915: Spinal Anesthesia Versus Combined Sciatic-femoral Nerve Block for Outpatient Knee Arthroscopy
Official title: Spinale Unilaterale o Blocco Nervoso Periferico Per le Artroscopie di Ginocchio in Day Surgery. Confronto Prospettico Randomizzato
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Knee Arthritis
Lead sponsor: ASST Gaetano Pini-CTO
Sponsor class: OTHER
First posted: 2015-03-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study is to compare the time of home discharge in day-case patients receiving either a spinal anesthesia or a combined sciatic-femoral nerve block for knee arthroscopy

Detailed description: Two groups: the first receive a spinal anesthesia injecting 2% hyperbaric prilocaine 40 mg with the patients in lateral decubitus and the surgical limb declive, the second a combined ultrasound-guided sciatic-femoral nerve block injecting 25 ml of 2% mepivacaine solution.

Onset time, performance time, duration of the block, time of voiding, as well as the time of home discharge will be evaluated.

Eligibility criteria: Inclusion Criteria:

* outpatients knee arthroscopy

Exclusion Criteria:

* diabetes
* allergy to local anesthetic
* patient refusal
* chronic opiods assumption

Primary outcomes:
measure: Time to home discharge
timeFrame: 12 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Istituto Ortopedico G. Pini
state: Milano
Study officials:
References: